APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers

Neurology

Volumn 66, Issue 9, 2006, Pages 1373-1383

  Burwick, R M ^a   Ramsay, P P ^a   Haines, J L ^b   Hauser, S L ^c   Oksenberg, J R ^c   Pericak Vance, M A ^d   Schmidt, S ^d   Compston, A ^e   Sawcer, S ^e   Cittadella, R ^f   Savettieri, G ^g   Quattrone, A ^f,h   Polman, C H ⁱ   Uitdehaag, B M J ⁱ   Zwemmer, J N P ⁱ   Hawkins, C P ^j   Ollier, W E R ^k   Weatherby, S ^l   Enzinger, C ^m   Fazekas, F ^m   Schmidt, H ^m   Schmidt, R ^m   Hillert, J ⁿ   Masterman, T ⁿ   Hogh, P ^o   Niino, M ^p   Kikuchi, S ^p   Maciel, P ^q   Santos, M ^q   Rio, M E ^r   Kwiecinski, H ^s   Zakrzewska Pniewska, B ^s   Evangelou, N ^t   Palace, J ^u   Barcellos, L F ^a,c,v   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^k University Medical School   (United Kingdom)

^l DERRIFORD HOSPITAL   (United Kingdom)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o Mental Health Services CPH   (Denmark)

^p HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF MINHO   (Portugal)

^r HOSPITAL DE SÃO JOÃO   (Portugal)

^s MEDICAL UNIVERSITY OF WARSAW   (Poland)

^t QUEEN S MEDICAL CENTRE   (United Kingdom)

^u UNIVERSITY OF OXFORD   (United Kingdom)

^v DIVISION OF RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON; UNCLASSIFIED DRUG;

ARTICLE; BIOSIS; COCHRANE LIBRARY; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EMBASE; EXPANDED DISABILITY STATUS SCALE; FAMILIAL DISEASE; GENOTYPE; HEREDITY; HUMAN; MEDLINE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL;

ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MULTIPLE SCLEROSIS; PEDIGREE; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEVERITY OF ILLNESS INDEX;

EID: 33646712168     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000210531.19498.3f     Document Type: Article

References (109)

1. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun 2005;6:375-387.
2. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-110.
3. Rall SC Jr., Weisgraber KH, Mahley RW. Human apolipoprotein E: the complete amino acid sequence. J Biol Chem 1982;257:4171-4178.
4. Mahley RW. Apolipoprotein E cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
5. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-530.
6. Weisgraber KH, Rall SC Jr., Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-9083.
7. Barcellos LF, Thomson G, Carrington M, et al. Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis. Evidence of a new susceptibility locus in Caucasian and Chinese patients. JAMA 1997;278:1256-1261.
8. Ballerini C, Campani D, Rombola G, et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett 2000;296:174-176.
9. Chapman J, Vinokurov S, Achiron A, et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001;56:312-316.
10. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:203-205.
11. Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001;57:853-857.
12. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. Mult Scler 2003;9:382-386.
13. Oliveri RL, Cittadella R, Sibilia G, et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999;100:290-295.
14. Pirttila T, Haanpaa M, Mehta PD, Lehtimaki T. Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster. Acta Neurol Scand 2000;102:94-98.
15. Savettieri G, Andreoli V, Bonavita S, et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003;250:1094-1098.
16. Weatherby SJ, Mann CL, Davies MB, et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000;6:32-36.
17. Lucotte GL. Confirmation of a gene for multiple sclerosis (MS) to chromosome region 19q13.3. Genet Couns 2002;13:133-138.
18. D'Alfonso S, Nistico L, Zavattari P, et al. Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. Eur J Hum Genet 1999;7:377-385.
19. Reunanen K, Finnila S, Laaksonen M, et al. Chromosome 19q13 and multiple sclerosis susceptibility in Finland: a linkage and two-stage association study. J Neuroimmunol 2002;126:134-142.
20. Kantarci OH, de Andrade, M Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-159.
21. Cocco E, Marrosu MG. Is multiple sclerosis severity a genetically influenced trait? Neurol Sci 2000;21(4 suppl 2):S843-847.
22. Becker KG. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001;57:2148-2149.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
24. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
25. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002;70:708-717.
26. Goodkin DE, Doolittle TH, Hauser SL, Ransohoff RM, Roses AD, Rudick RA. Diagnostic criteria for multiple sclerosis research involving multiply affected families. Arch Neurol 1991;48:805-807.
27. Rubinsztein DC, Hanlon CS, Irving RM, et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol Cell Probes 1994;8:519-525.
28. Hagerup L, Hansen PF. [An investigation of 50-year-old persons in Glostrup in 1964-65.] Ugeskr Laeger 1968;130:1145-1148.
29. Schmidt R, Schmidt H, Fazekas F, et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997;28:951-956.
30. Treves TA, Bornstein NM. APOE-e4 in age-related memory complaints and Alzheimer's disease. Eur J Neurol 1996;3:515-518.
31. Nikkila M, Pitkajarvi T, Koivula T, et al. Women have a larger and less atherogenic low density lipoprotein particle size than men. Atherosclerosis 1996;119:181-190.
32. Chapman J, Sylantiev C, Nisipeanu P, Korczyn AD. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999;56:1484-1487.
33. Gervais A, Gaillard O, Plassart E, Reboul J, Fontaine B, Schuller E. Apolipoprotein E polymorphism in multiple sclerosis. Ann Clin Biochem 1998;35:135-136.
34. Schreiber K, Otura AB, Ryder LP, et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5deletion mutation, apolipoprotein E). Mult Scler 2002;8:295-298.
35. Masterman T, Zhang Z, Hellgren D, et al. APOE genotypes and disease severity in multiple sclerosis. Mult Scler 2002;8:98-103.
36. Kantarci OH, Hebrink DD, Achenbach SJ, et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004;62:811-814.
37. Guerrero AL, Bueno V, Hernandez MT, Martin-Serradilla JI, Carrasco E, Cuadrado I. [Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis.] Neurologia 2003;18:146-148.
38. Santos M, do Carmo Costa M, EditeRio M, et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004;10:153-157.
39. Carlin C, Murray L, Graham D, Doyle D, Nicoll J. Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE epsilon2 allele. J Neuropathol Exp Neurol 2000;59:361-367.
40. Lancaster A, Nelson MP, Meyer D, Thomson G, Single RM. PyPop: a software framework for population genomics: analyzing large-scale multi-locus genotype data. Pac Symp Biocomput 2003:514-525.
41. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet 2000;67:146-154.
42. Martin ER, Bass MP, Kaplan NL. Correcting for a potential bias in the pedigree disequilibrium test. Am J Hum Genet 2001;68:1065-1067.
43. Martin ER, Bass MP, Gilbert JR, Pericak-Vance MA, Hauser ER. Genotype-based association test for general pedigrees: the genotype-PDT. Genet Epidemiol 2003;25:203-213.
44. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-716.
45. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150-158.
46. Sawcer S, Maranian M, Setakis E, et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002;125:1337-1347.
47. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-266.
48. Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOB-epsilon 4. Ann Neurol 2004;55:563-569.
49. Ferri C, Sciacca FL, Veglia F, et al. APOE epsilon2-4 and -491 polymorphisms are not associated with MS. Neurology 1999;53:888-889.
50. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
51. Hogh P, Oturai A, Schreiber K, et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000;6:226-230.
52. Fazekas F, Strasser-Fuchs S, Schmidt H, et al. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;69:25-28.
53. Smith JD. Apolipoprotein E4: an allele associated with many diseases. Ann Med 2000;32:118-127.
54. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999;63:301-310.
55. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150-151.
56. Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993;33:281-285.
57. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-476.
58. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996;13:469-471.
59. Sawcer S, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-468.
60. Kuokkanen S, Gschwend M, Rioux JD, et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997;61:1379-1387.
61. Broadley S, Sawcer S, D'Alfonso S, et al. A genome screen for multiple sclerosis in Italian families. Genes Immun 2001;2:205-210.
62. Coraddu F, Sawcer S, D'Alfonso S, et al. A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet 2001;9:621-626.
63. Akesson E, Oturai A, Berg J, et al. A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes Immun 2002;3:279-285.
64. Ban M, Stewart GJ, Bennetts BH, et al. A genome screen for linkage in Australian sibling-pairs with multiple sclerosis. Genes Immun 2002;3:464-469.
65. Eraksoy M, Kurtuncu M, Akman-Demir G, et al. A whole genome screen for linkage in Turkish multiple sclerosis. J Neuroimmunol 2003;143:17-24.
66. Hensiek AE, Roxburgh R, Smilie B, et al. Updated results of the United Kingdom linkage-based genome screen in multiple sclerosis. J Neuroimmunol 2003;143:25-30.
67. Kenealy SJ, Babron MC, Bradford Y, et al. A second-generation genomic screen for multiple sclerosis. Am J Hum Genet 2004;75:1070-1078.
68. Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-467.
69. Haines JL, Terwedow HA, Burgess K, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 1998;7:1229-1234.
70. Traherne JA, Barcellos LF, Sawcer SJ, et al. Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. Hum Mol Genet 2005.
71. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-1112.
72. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
73. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
74. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002;70:985-993.
75. Li YJ, Pericak-Vance MA, Haines JL, et al. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics 2004;5:209-213.
76. Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004;62:2005-2009.
77. Mahley RW, Rall SC Jr., Apolipoprotein E. Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
78. Horsburgh K, Graham DI, Stewart J, Nicoll JA. Influence of apolipoprotein E genotype on neuronal damage and apoE immunoreactivity in human hippocampus following global ischemia. J Neuropathol Exp Neurol 1999;58:227-234.
79. Gelman BB, Goodrum J, Bouldin TW. Macrophage apolipoprotein synthesis and endoneurial distribution as a response to segmental demyelination. J Neuropathol Exp Neurol 1991;50:383-407.
80. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-856.
81. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117-139.
82. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-191.
83. Campbell CD, Ogburn EL, Lunetta KL, et al. Demonstrating stratification in a European American population. Nat Genet 2005;37:868-872.
84. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004;36:388-393.
85. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 1996;59:983-989.
86. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
87. Lucchinetti C, Bruck W. The pathology of primary progressive multiple sclerosis. Mult Scler 2004;10 Suppl 1:S23-30.
88. Thompson A, Polman CH, Miller DH. Primary progressive multiple sclerosis. Brain 1997;120:1085-1096.
89. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler 2004;10 Suppl 1:S2-7.
90. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
91. Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 1997;49:378-385.
92. Cocco E, Sotgiu A, Costa G, et al. HLA-DR,DQ and APOE genotypes and gender influence in Sardinian primary progressive MS Neurology 2005;64:564-566.
93. Al-Shammri S, Fatania H, Al-Radwan R, Akanji AO. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects. Clin Chim Acta 2005;351:203-207.
94. Zwemmer J, Uitdehaag B, van Kamp G, Barkhof F, Polman C. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004;63:1139; author reply 1139.
95. Djousse L, Myers RH, Coon H, Arnett DK, Province MA, Ellison RC. Smoking influences the association between apolipoprotein E and lipids: the National Heart, Lung, and Blood Institute Family Heart Study. Lipids 2000;35:827-831.
96. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001;154:69-74.
97. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005;128:1461-1465.
98. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420.
99. Hohol M, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997;54:1018-1025.
100. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004;251:1208-1214.
101. Masterman T, Hillert J. The telltale scan: APOE epsilon4 in multiple sclerosis. Lancet Neurol 2004;3:331.
102. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S8-14.
103. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158:183-193.
104. Neuhaus O, Stuve O, Archelos JJ, Hartung HP. Putative mechanisms of action of statins in multiple sclerosis - comparison to interferon-beta and glatiramer acetate. J Neurol Sci 2005;233:173-177.
105. Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004;3:369-371.
106. Stuve O, Prod'homme T, Youssef S, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004;4:237-244.
107. Gaillard O, Gervais A, Meillet D, et al. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J Neurol Sci 1998;158:180-186.
108. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004;10:266-271.
109. Zwemmer JN, van Veen T, van Winsen L, et al. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004;10:272-277.